M
Martina Mittlböck
Researcher at Medical University of Vienna
Publications - 157
Citations - 5066
Martina Mittlböck is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 36, co-authored 153 publications receiving 4524 citations. Previous affiliations of Martina Mittlböck include University of Vienna.
Papers
More filters
Journal ArticleDOI
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
Michael Gnant,Brigitte Mlineritsch,G. Luschin-Ebengreuth,Franz Kainberger,Helmut Kässmann,Jutta Claudia Piswanger-Sölkner,Michael Seifert,Ferdinand Ploner,Christian Menzel,Peter Dubsky,Florian Fitzal,Vesna Bjelic-Radisic,Günther G. Steger,Richard Greil,Christian Marth,Ernst Kubista,Hellmut Samonigg,Peter Wohlmuth,Martina Mittlböck,Raimund Jakesz +19 more
TL;DR: A randomised, open-label, phase III, 4-arm trial comparing tamoxifen and goserelin versus anastrozole and zoledronic acid for preventing bone loss associated with adjuvant endocrine therapy and reports on long-term findings of bone-mineral density (BMD) during 3 years of treatment and 2 years after completing adjuant treatment with or without zoledronics acid.
Journal ArticleDOI
Explained variation for logistic regression
TL;DR: In this article, the authors review twelve measures that have been suggested or might be useful to measure explained variation in logistic regression models, and compare their performance in an empirical study.
Journal ArticleDOI
The prevalence of hemorrhoids in adults
Stefan Riss,Friedrich Anton Weiser,Katrin Schwameis,Thomas Riss,Martina Mittlböck,Gottfried Steiner,Anton Stift +6 more
TL;DR: Hemorrhoids occur frequently in the adult general population and a high BMI can be regarded as an independent risk factor for hemorrhoids.
Journal Article
TP53 Mutation and p53 Overexpression for Prediction of Response to Neoadjuvant Treatment in Breast Cancer Patients
Daniela Kandioler-Eckersberger,Carmen Ludwig,Margarethe Rudas,Sonja Kappel,Elisabeth Janschek,Catharina Wenzel,Hermine Schlagbauer-Wadl,Martina Mittlböck,Michael Gnant,Günter Steger,Raimund Jakesz +10 more
TL;DR: TP53 mutations, as well as p53 protein overexpression, to be associated with response to chemotherapy, whereas clinical response to FEC was found to be dependent on normal p53, the cytotoxicity of paclitaxel was related to defective p53.
Journal ArticleDOI
Efficacy of liver transplantation for alcoholic cirrhosis with respect to recidivism and compliance.
Gabriela A. Berlakovich,Rudolf Steininger,Friedrich Herbst,Murat Barlan,Martina Mittlböck,Ferdinand Mühlbacher +5 more
TL;DR: Unwillingness to offer OLT to individuals with alcoholic liver disease because of failure to demonstrate 100% long-term abstinence appears difficult to defend in the face of good results in survival, compliance, and social rehabilitation.